Additive Effects of drug transporter genetic polymorphisms on irinotecan pharmacokinetics/pharmacodynamics in Japanese cancer patients

Kimie Sai,Yoshiro Saito,Keiko Maekawa,Su-Ryang Kim,Nahoko Kaniwa,Tomoko Nishimaki-Mogami,Jun-ichi Sawada,Kuniaki Shirao,Tetsuya Hamaguchi,Noboru Yamamoto,Hideo Kunitoh,Yuichiro Ohe,Yasuhide Yamada,Tomohide Tamura,Teruhiko Yoshida,Yasuhiro Matsumura,Atsushi Ohtsu,Nagahiro Saijo,Hironobu Minami

Additive Effects of drug transporter genetic polymorphisms on irinotecan pharmacokinetics/pharmacodynamics in Japanese cancer patients

2010

Kimie Sai
Yoshiro Saito
Keiko Maekawa
Su-Ryang Kim
Nahoko Kaniwa
Tomoko Nishimaki-Mogami
Jun-ichi Sawada
Kuniaki Shirao
Tetsuya Hamaguchi
Noboru Yamamoto
Hideo Kunitoh
Yuichiro Ohe
Yasuhide Yamada
Tomohide Tamura
Teruhiko Yoshida
Yasuhiro Matsumura
Atsushi Ohtsu
Nagahiro Saijo
Hironobu Minami

Purpose Effects of genetic polymorphisms/variations of ABCB1, ABCC2, ABCG2 and SLCO1B1 in addition to “UGT1A1*28 or *6” on irinotecan pharmacokinetics/pharmacodynamics in Japanese cancer patients were investigated.

Keywords:

SLCO1B1
Pharmacology
Genetic variability
Cancer
Pharmacodynamics
Irinotecan
Genotype
Combination therapy
Medicine
Pharmacokinetics
Drug

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations